A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC
N/A
Terminated
NCT02771795
| Condition | Breast Neoplasms |
|---|
| Phase | N/A |
|---|
| Sponsor | Samsung Bioepis Co., Ltd. |
|---|
| Status | Terminated |
|---|
| Enrollment | 538 participants |
|---|
| Interventions | Herceptin (trastuzumab), SB3 (proposed trastuzumab biosimilar) |
|---|
| Start date | Apr, 2016 |
|---|
| Completion date | Dec, 2020 |
|---|
| Results posted | Feb 2, 2024 |
|---|
Summary
A Long-term Follow-up Study for Cardiac Safety in the Patients with HER2 Positive Early or Locally Advanced Breast Cancer Who Have Completed the SB3-G31-BC
Number of Subjects With Asymptomatic Significant LVEF Decrease
approximately 56 months (median follow-up duration) · Participants
| Herceptin (Trastuzumab) | 2 Participants |
|---|
| SB3 (Proposed Trastuzumab Biosimilar) | 1 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.